Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

Monzr M. Al Malki, Kaitlyn London, Janna Baez, Yu Akahoshi, William J. Hogan, Aaron Etra, Hannah Choe, Elizabeth Hexner, Amelia Langston, Sunil Abhyankar, Doris M. Ponce, Zachariah DeFilipp, Carrie L. Kitko, Kehinde Adekola, Ran Reshef, Francis Ayuk, Alexandra Capellini, Chantiya Chanswangphuwana, Matthias Eder, Gilbert EngIsha Gandhi, Stephan Grupp, Sigrun Gleich, Ernst Holler, Nora Rebeka Javorniczky, Stelios Kasikis, Steven Kowalyk, George Morales, Umut Özbek, Wolf Rösler, Nikolaos Spyrou, Gregory Yanik, Rachel Young, Yi Bin Chen, Ryotaro Nakamura, James L.M. Ferrara, John E. Levine

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease'. Together they form a unique fingerprint.

Medicine & Life Sciences